Yukinori Yamauchi

Yukinori Yamauchi

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2007 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
AAAlex Avdeef
Alex Avdeef
SBStefanie Bendels
Stefanie Bendels
LDL.I. Di
L.I. Di
BFBernard Faller
Bernard Faller
MKManfred Kansy
Manfred Kansy
YYYukinori Yamauchi
Yukinori Yamauchi

19 March 2015 in ACS Sustainable Chemistry & Engineering
Verified
Journal Article
Closed access
Yoshinari SawamaYoshinari Sawama
Yoshinari Sawama
MNMiki Niikawa
Miki Niikawa
YYYuki Yabe
Yuki Yabe
RGRyota Goto
Ryota Goto
TKTakahiro Kawajiri
Takahiro Kawajiri
Hironao SajikiHironao Sajiki
Hironao Sajiki

1 August 2013 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Satomi OnoueSatomi Onoue
Satomi Onoue
YKYoshiki Kojo
Yoshiki Kojo
HSHiroki Suzuki
Hiroki Suzuki
KYKayo Yuminoki
Kayo Yuminoki
KKKeitatsu Kou
Keitatsu Kou
SYShizuo Yamada
Shizuo Yamada

1 November 1994 in The Journal of Physical Chemistry
Verified
Journal Article
Closed access
MKMasayuki Kuzuya
Masayuki Kuzuya
KMKazue Morisaki
Kazue Morisaki
JNJunji Niwa
Junji Niwa
YYYukinori Yamauchi
Yukinori Yamauchi
KXKaijun Xu
Kaijun Xu

1 January 2012 in Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
Satomi OnoueSatomi Onoue
Satomi Onoue
YKYoshiki Kojo
Yoshiki Kojo
YAYosuke Aoki
Yosuke Aoki
YKYohei Kawabata
Yohei Kawabata
YYYukinori Yamauchi
Yukinori Yamauchi
SYShizuo Yamada
Shizuo Yamada
In the present study, amorphous solid dispersion (ASD) formulations of tranilast (TL) with 8 hydrophilic polymers were prepared by a solvent evaporation method with the aim of improving dissolution behavior in gastric fluid and thereby enhancing oral bioavailability. The physicochemical properties were characterized with a focus on morphology, crystallinity, thermal behavior, dissolution, drug-polymer interaction, and stability. Of all TL formulations, ASD formulation with Eudragit EPO exhibited the highest improvement in dissolution behavior with a 3,000-fold increase in the first-order dissolution rate under acidic conditions (pH 1.2). Spectroscopic studies using infrared and near-infrared analyses revealed the drug-polymer interaction in the Eudragit EPO-based ASD formulation. On the basis of dissolution, crystallinity, and stability data, the maximum allowable drug load in the Eudragit EPO-based ASD formulation was deduced to be ca. 50%. Pharmacokinetic profiling of orally dosed TL formulations in rats was also carried out using UPLC/ESI-MS. After oral administration of the Eudragit EPO-based ASD formulation in rats, enhanced TL exposure was observed with an increase of oral bioavailability by 19-fold, and the variation of AUC was ca. 4 times lower than that with crystalline TL. With these data, the ASD approach could be a viable formulation strategy for enhancing the wettability and oral bioavailability of TL, resulting in improved therapeutic potential of TL for the treatment of inflammatory diseases.

1 February 2011 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
Satomi OnoueSatomi Onoue
Satomi Onoue
YAYosuke Aoki
Yosuke Aoki
YKYohei Kawabata
Yohei Kawabata
TMTakuya Matsui
Takuya Matsui
KYKiyoshi Yamamoto
Kiyoshi Yamamoto
SYShizuo Yamada
Shizuo Yamada